SLRN NASDAQ
Agoura Hills, CA 91301
US
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| AyurMaya Capital Man | D-Return | 9,334,735 | — | 2025-05-21 |
| Kim Mina | D-Return | 190,114 | $7.68 | 2025-05-21 |
| Kim Mina | D-Return | 1,195,856 | $4.13 | 2025-05-21 |
| Kim Mina | D-Return | 85,226 | $18.00 | 2025-05-21 |
| Kim Mina | D-Return | 362,719 | $5.88 | 2025-05-21 |